Over the past decade, the reactivation of TWIST embryonic transcription factors has been described as a frequent event and a marker of poor prognosis in an impressive array of human cancers. Growing evidence now supports the premise that these cancers hijack TWIST's embryonic functions, granting oncogenic and metastatic properties. In this review, we report on the history and recent breakthroughs in understanding TWIST protein functions and the emerging role of the associated epithelialmesenchymal transition (EMT) in tumorigenesis. We then broaden the discussion to address the general contribution of reactivating embryonic programs in cancerogenesis.
Introduction
Originally shown to be central to embryonic development, aberrant functions of the TWIST transcription factor family have grown and spread into many facets of tumor development and progression. The initial link between these proteins and cancer identified TWIST1 as a pro-metastatic protein in breast carcinomas. Since then, the roles of this family (TWIST1 and TWIST2) in various types of solid human cancers have expanded to include the development of primary tumor growth, cell dissemination and chemoresistance. Recent progress in understanding TWIST physiological and oncogenic functions highlights a number of parallels suggesting that reactivation of TWIST-associated embryonic programs de facto contribute to tumor progression. The aim of this review is to evaluate the status of the field by highlighting the most recent breakthroughs in understanding TWIST functions and identifying future avenues of investigation. We will attempt to substantiate the parallel between the embryonic and oncogenic properties of TWIST proteins and, in particular, address the role of the associated epithelial-mesenchymal transition in tumor progression and cell dissemination.
TWIST proteins are pleiotropic gene regulators
TWIST proteins belong to the large family of basic Helix-Loop-Helix (bHLH) transcription factors originally found to modulate the expression of various target genes through canonical E-box responsive elements (Lee et al., 1997; Yin et al., 1997) . Well conserved during evolution, two TWIST genes exist in vertebrates, TWIST1 and TWIST2 (formerly Dermo-1). The TWIST proteins display a high degree of sequence similarity in their C-terminal half, including the bHLH domain and a 'TWIST-box' protein interaction surface and are more divergent in their N terminus (Wolf et al., 1991; Li et al., 1995; Bialek et al., 2004) . Among the bHLH proteins, TWIST transcription factors are unique in their ability to form functional homo-and heterodimers. These two types of complexes were found to display distinct, even antagonistic, properties as exemplified by the mesoderm specification and the subsequent allocation of mesodermal cells to the somatic muscle fate by Twi-Twi (Twi is the Drosophila TWIST ortholog) homodimers whereas heterodimers between Twi and the E protein homolog Daughterless (Da) repress genes required for somatic myogenesis (Castanon et al., 2001) . The balance between TWIST1 homoand heterodimers (TWIST1-TCF3/E2A (TE) or TWIST1-Hand2 protein complexes) was also shown to direct appropriate limb development as well as cranial suture patterning and fusion in mice (Firulli et al., 2005; Connerney et al., 2006 Connerney et al., , 2008 , suggesting that this TWIST-regulatory mechanism is conserved across species. These different dimers further differ in stability as the association of TWIST with TCF3/E2A proteins protect TWIST from the ubiquitin-dependent proteasome degradation pathway (Hayashi et al., 2007) . Multiple factors, including the relative amounts of the binding partners, their phosphorylation status as well as the expression of Id HLH proteins (that preferentially interact with E2A, titrating it and thereby favoring TWIST homodimers) determine the relative amounts of both types of dimers and thereby TWIST activity (for a recent review, see Firulli and Conway, 2008) .
TWIST proteins behave either as transcriptional repressors, recruiting histone deacetylases or inhibiting acetyl-transferases, or as transcriptional activators Gong and Li 2002; Pan et al., 2009) . These functions are independent of the dimer type and appear to be tissue-dependent in Drosophila. This switchable behavior is linked to a particular conserved domain of Da, which inactivates both Twi and Da transactivation domains through an intramolecular mechanism (Wong et al., 2008) . As the domain is conserved across species, we anticipate that it similarly dictates TWIST tissue-specific effects in higher organisms.
In addition, TWIST proteins directly interact with several other transcription factors, including MyoD, MEF2, RUNX1, RUNX2, PGC1-a, p53 and NF-kB, and inhibit their activities (Spicer et al., 1996; Hamamori et al., 1999; Sosic et al., 2003; Bialek et al., 2004; Sharabi et al., 2008; Shiota et al., 2008; Pan et al., 2009) . As discussed in the following section, inactivation of these transcription factors provides TWIST proteins with the ability to inhibit an array of differentiation pathways while endowing survival properties.
Physiological functions of Twist proteins
Embryonic development and tissue specification Twi was originally identified in Drosophila as a zygotic developmental gene crucial for the establishment of the ventral furrow, a prerequisite for the development of all mesoderm-derived internal organs (Thisse et al., 1987) . In mice, Twist1 haploinsufficiency produces viable offspring but leads to abnormal craniofacial structures and polydactyly in the hind limb, a phenotype reminiscent to the dominantly inherited Saethre-Chotzen syndrome in humans where TWIST1 is mutated (Bourgeois et al., 1998) . Twist 1 À/À mice, in contrast to flies, undergo normal gastrulation but die at E10.5-11 displaying severe defects in closure of the cephalic neural tube, deficient cranial mesoderm, malformed branchial arches and facial primordium, and retarded limb bud development. TWIST1 therefore acts after mesoderm specification in vertebrates, but remains essential in mesoderm differentiation including muscle, cartilage and osteogenic cell lineages (Hebrok et al., 1994; Spicer et al., 1996; Lee et al., 1999) . Mesoderm formation in vertebrates is actually controlled by SNAI1 and SNAI2 transcription factors (Nieto et al., 1994; Nieto 2002) . All three proteins are functionally related, sharing the ability to promote a cellular transdifferentiation process known as the epithelial-mesenchymal transition (EMT). Originally depicted as a mechanism for mesoderm formation in avian embryos, EMT has since been associated with multiple developmental processes including neural crest formation, somitogenesis, sclerotome formation and cardiac valve development from endocardium and consists of a loss of cell to cell contact, loss of cell polarity and the acquisition of motility (for recent reviews see (Baum et al., 2008; Nakaya and Sheng 2008) ). The mechanisms by which TWIST proteins promote EMT are discussed in the next section.
Twist1 À/À mice also present a significant increase in apoptotic cells, especially in the developing sclerotome (Chen and Behringer 1995) . This cell death could reflect TWIST1 anti-apoptotic properties as TWIST proteins also behave as key regulators of the p53 oncosuppressive protein and as major effectors of the NF-kB survival pathway (Maestro et al., 1999; Sosic et al., 2003; Puisieux et al., 2006; Doreau et al., 2009) . Cell death might also result from inappropriate premature differentiation as evidence strongly suggests a role of TWIST in maintaining myoblast progenitor cells during development (Hebrok et al., 1994) . In vertebrates, TWIST1 is initially expressed throughout the somatic mesoderm and is subsequently silenced in the forming myotome (Hopwood et al., 1989; Wolf et al., 1991) . Similarly, in Drosophila, Twi is expressed in the somatic mesoderm at high levels before differentiation and is required for differentiation of the somatic muscles (Baylies and Bate 1996) . Its expression is maintained in clusters of undifferentiated proliferating cells that will give rise to adult myoblasts and ultimately muscles throughout the larval and early pupal stages (Bate et al., 1991) . TWIST1 inhibitory properties rely on their ability to interact and inactivate myogenic factors such as MyoD and MEF2 (Spicer et al., 1996; Hamamori et al., 1997) .
The TWIST1 protein is also likely to be important for maintaining the immature phenotype of chondrocytes. By comparing chick caudal and cephalic sternal chondrocytes that display distinct capabilities to terminally differentiate, TWIST1 was found to inhibit chondrocyte differentiation by turning down RUNX2 expression (Dong et al., 2007) . Accordingly, in mice, Twist1 mRNA was found to be expressed in immature chrondrocytes whereas the transcript is undetectable in more mature ones (Hinoi et al., 2006) . Similarly, TWIST1 was found to inhibit osteoblastic differentiation. In mice, Twist1 is downregulated during endochondral and intramembranous fetal bone marrow development (Alborzi et al., 1996) . During calvaria and suture development, Twist1 is expressed at sides of immature bone cells and to less extent in more mature ones (Rice et al., 2000; Connerney et al., 2006) . In addition, in mice and humans (Saethre-Chotzen syndrome), haploinsufficiency of TWIST1 has been shown to cause craniosynostosis, a premature closure of the cranial sutures and limb development abnormalities (Howard et al., 1997; el Ghouzzy et al., 1997; Bourgeois et al., 1998; Gripp et al., 2000) . This phenotype has been linked with premature osteoblastic differentiation, mediated by an alteration of the balance of TWIST homo-and TWIST-E2A (TE) heterodimer types and inhibition of RUNX2 by TWIST proteins (Bialek et al., 2004; Connerney et al., 2006) . TWIST1 is also expressed in lateral plate mesoderm, which generates endothelial precursor cells (Hopwood et al., 1989) . Finally, using an elegant approach combining knock-down by morpholinos and complementation assays, both TWIST and SNAI2 transcription factors were found to function downstream of c-MYC and to be essential for normal blood vessel formation in Xenopus laevis (Rodrigues et al., 2008) .
Although its expression is barely detectable at E9.5, Twist2 is expressed at E10.5 in the limbs buds and body wall, a pattern progressively restricted to the craniofacial mesenchyme, chondrogenic precursors and dermis in the skin. Accordingly, Twist2 might have a role in the differentiation of distinct subsets of vertebral precursor TWIST embryonic and oncogenic properties S Ansieau et al cells during sclerotome maturation and in skin development suggesting functional divergences and redundancies between the two TWIST proteins (Li et al., 1995) .
Twist proteins in adult organisms
TWIST proteins might similarly determine cell fate of adult stem cells. In Drosophila pupals, Twi was found to be expressed within the adult muscle precursor cells, which invade the larval oblique muscles and was determined as essential for their splitting into dorsal longitudinal muscles found in the thorax of the adult fly (Cripps and Olson, 1998) . Ectopic expression of TWIST1 or TWIST2 in human bone marrow-derived mesenchymal stromal/stem cells (MSC) was found to maintain an immature stromal phenotype, to inhibit their osteo-chondrogenic potential and conversely to increase their adipocyte potential, strengthening their role in cell fate determination (Isenmann et al., 2009) . TWIST2 was additionally found to be expressed in granulocyte-macrophage progenitors, preventing their proliferation and differentiation into macrophages, neutrophils and basophils, through the inactivation of both RUNX1 and C/EBPa transcription factors (Sharabi et al., 2008) . On the basis of human multiple tissue Northern blot analysis, TWIST1 expression was originally defined as being restricted to mesoderm-derived tissues including placenta, heart and skeletal muscles (Wang et al., 1997) , presumably in precursor cells. Recently, the protein was found to be additionally expressed in brown fat and to be essential for its function in adaptative thermogenesis, a process that consists of metabolizing fat as heat. TWIST1 behaves as a negative regulator of the PGC1-a transcription factor, the key regulator of the entire program of thermogenesis, by scaffolding together PGC1-a with a class II histone deacetylase to silent its target genes. Twist1 depletion is sufficient to provide a remarkable obesity-resistant phenotype, elevated oxygen consumption and mitochondrial biogenesis linking for the first time TWIST1 to cell metabolism (Pan et al., 2009) .
Although Twist1 knockout is lethal at early development stages, Twist2 À/À mice die shortly after birth (Chen and Behringer, 1995; Sosic et al., 2003) from a severe wasting of body tissue and anemia (cachexia), because of the overexpression of pro-inflammatory cytokines (Sosic et al., 2003) . This pro-inflammatory cytokine production contributes to pleiotropic effects including depletion of lipid and glycogen stores and postnatal atrophy of multiple tissues due to extensive apoptosis. Dissection of the associated molecular mechanisms firstly pointed out that both Twist genes are direct targets of NF-kB and contribute to regulate its ability through a negative feedback mechanism. TWIST proteins physically interact with NF-kB and specifically prevent its ability to activate the TNFa, IL-1b and IL-6 pro-inflammatory cytokine-encoding genes (Sosic et al., 2003) . Recently, in mature myeloid cells, TWIST2 was confirmed to downregulate the inflammatory responses by preventing the production of pro-inflammatory cytokines and chemokines (such as IL-12, IFNg, IL-1, TNFa, IL-6, MCP-1, MIP-1a) likely through the inactivation of both C/EBPa and NF-kB but also by promoting the production of the anti-inflammatory IL-10 cytokine (Sharabi et al., 2008) . Finally, TWIST proteins alleviate TNFa induction in response to T-cell receptor (TCR) activation and thereby contribute to the negative crossregulation of TNFa by anti-inflammatory pathways (Sharif et al., 2006) . TWIST proteins were also found to function downstream of TCR in T-helper 1 (Th1) memory lymphocytes and to inhibit these potent inducers of inflammation. Recurrent stimulation of Th1 T-lymphocytes by the cognate antigen leads to the gradual activation of Twist1 through coordinated action of NFAT, NF-kB and activated STAT4 transcription factors. TWIST1 expression does not interfere with the homing of the Th1 cell population to the inflamed tissue nor lymph node draining, instead its expression significantly lowers the histological score of inflammation and tissue destruction (Niesner et al., 2008) . Overall, these observations depict TWIST proteins as key-negative mediators of the inflammatory response.
Overexpression of TWIST oncoproteins in human cancers
Both TWIST genes were found to be overexpressed in a large set of human and murine tumors including a variety of carcinomas as well as sarcomas, melanomas, gliomas and neuroblastomas (actual knowledge on TWIST1 expression in human cancers is recapitulated in Table 1 ) (Puisieux et al., 2006; Ansieau et al., 2008a) . In light of the high frequency of TWIST expression in cancers, the following sections will focus on the mechanisms leading to TWIST gene reactivation and its consequences on tumor progression.
Mechanisms of TWIST gene reactivation in cancers
Although the mechanisms leading to the aberrant reactivation of TWIST appear to be various and complex (Figure 1 ), they invariably result from the deregulation of signaling pathways that normally dictate the expression of the genes during the embryonic development. Interestingly, stress conditions seem to control both the physiological and aberrant expression of TWIST. Concomitant Hif1a and Twist expression during mouse development have been shown to have a role in the development of specific neural populations . Hypoxic conditions are similarly defined as potent inducers of TWIST1 expression in cancer cells thereby promoting cell dissemination to less hostile environment, presumably through its role in promoting an EMT Gort et al., 2008b) . Mechanical strains via integrin-mediated activation of the b-catenin pathway were also found to be essential in maintaining Twi expression during mesoderm invagination in the Drosophila embryo (Farge 2003; Brouzes et al., 2004; Desprat et al., 2008) . Whether such torsion-stresses, known to promote tumorigenesis (for a review, see (Butcher et al., 2009) ), also lead to TWIST embryonic and oncogenic properties S Ansieau et al TWIST induction during tumor progression remains to be determined. Nevertheless, initial arguments seem to support this assumption, as compression of colon sections of APC 168N/ þ mice (loss of one APC allele) is sufficient to induce the nuclear translocation of b-catenin and the resulting transcriptional activation of both c-MYC and TWIST1 genes (Whitehead et al., 2008) .
Post-translational modifications undoubtedly have an additional important role in regulating TWIST activity during development. As already mentioned, during development, TWIST homo-and heterodimers display distinct, even antagonist functions, impacting TWIST stability as well as the nature of the genetic program induced (Demontis et al., 2006; Hayashi et al., 2007; Firulli and Conway 2008) .
Although not yet shown, the mechanisms regulating TWIST dimerization are likely to also impinge on TWIST oncogenic and/or prometastatic properties.
Additional mechanisms susceptible to modulate TWIST expression have been reported. The DNA/ RNA binding protein YB1 was found to suppress cap-dependent translation initiation of growth promoting mRNAs and enhances the cap-independent translation initiation of EMT-inducing mRNAs including TWIST, SNAIL, ZEB1 and HIF1a, thereby promoting growtharrest and cell dissemination (Evdokimova et al., 2009 ). The methylation of TWIST1 was also depicted as taking part of an epigenetic program essential for EMT induction (Dumont et al., 2008) . Nevertheless, while TWIST1 promoter was indeed found to be hypermethylated in basal like and/or invasive breast cancers (Fackler et al., 2003; Dumont et al., 2008) , the methylation status of the TWIST1 promoter sequences and its expression are not correlated (Gort et al., 2008a) .
Oncogenic and pro-metastatic potentials of TWIST proteins
The prometastatic potential of TWIST1 was originally shown by comparison of isogenic murine cell lines. Successively, Twist1 expression and metastatic potential were found to correlate . In addition, Twist1 depletion was shown to prevent lung metastasis Figure 1 Schematic representation of the regulation of TWIST expression including the various signals leading to the activation of TWIST transcription, modulating mRNA translation as well as post-translational regulation mechanisms. Induction of TWIST expression in response to stress conditions or to the activation of signaling pathways and transcription factors as well as the regulation of TWIST activity by post-translation modifications are largely discussed in the review. Because of size restriction, the regulation of HMGA2, and potentially of its target gene TWIST1, by the let-7 miRNA has not been discussed. Please refer to (Thuault et al., 2006; Lee and Dutta, 2007; Mayr et al., 2007; Park et al., 2007) . T: TWIST protein, E: TCF3/E2A proteins, X: additional TWIST interacting transcription factors such as MyoD, PGC-1a, NF-kB or p53.
TWIST embryonic and oncogenic properties S Ansieau et al without affecting primary tumor formation, suggesting that TWIST1 specifically contributes to late cancer cell dissemination . This potential was suggested to rely on the ability of TWIST1 to induce an EMT and thereby promote motility, reminiscent of its embryonic biological properties. E-cadherin, encoded by the CDH1 gene, is generally defined as a guardian of the epithelial phenotype and loss of its expression is associated with tumor invasiness, metastatic dissemination and poor patient prognosis (Schipper et al., 1991; Oka et al., 1993; Umbas et al., 1994) . Repression of CDH1 gene by TWIST proteins is either direct Vesuna et al., 2008) or mediated by SNAI1, according to the cell type (Smit et al., 2009) . When direct, transcriptional repression might actually require TWIST stabilization through heterodimerization potentially in response to environmental signals, giving a rationale to the detection of TWIST-positive, E-cadherin-negative cells at the invasive fronts of malignant parathyroid neoplasia (Fendrich et al., 2009) . Interestingly, TWIST was inversely found to be activated following loss of E-cadherin expression (Onder et al., 2008) , raising the possibility that TWIST contributes to EMT induction by inducing the expression of mesenchymal genes rather than by repressing CDH1. Accordingly, a correlation between VIM, CDH2 (the vimentin and N-cadherin-encoding genes, respectively) and TWIST gene expressions is observed in breast cancer cell lines (Lombaerts et al., 2006) . In addition, TWIST1 was proposed to favor metastasis by inducing the miR-10b/HoxD10/RhoC signaling pathway (Ma et al., 2007) . Nevertheless, the correlation between miR-10b and distant metastasis or poor prognosis remains a matter of discussion (Gee et al., 2008; Tavazoie et al., 2008) .
Another aspect of the TWIST proteins' dark side relies on their ability to override oncogene-induced senescence and apoptosis, the natural barriers activated to constrain cell growth in premalignant lesions (Bartkova et al., 2005; Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Gorgoulis et al., 2005) . Originally, the anti-apoptotic properties of TWIST proteins were deciphered through a functional screen using the escape of c-MYC-induced apoptosis as the determinant. The two related transcription factors were found to alleviate ARF induction and the consequent p53 stabilization in response to the oncogenic insult (Maestro et al., 1999) . In agreement with these conclusions, our group identified TWIST1 reactivation as the prevalent mechanism of p53 functional inactivation in neuroblastomas, preventing N-MYC-induced apoptosis and thus tumor progression (Valsesia-Wittmann et al., 2004) . Various studies have since shown that TWIST proteins actually negatively regulate each step leading to p53 target gene activation, including p53 stabilization, its activation through post-translational modifications, its DNA binding and trans-activation potential Xie et al., 2001; Stasinopoulos et al., 2005; Shiota et al., 2008) .
Recently, in addition our group showed that TWIST proteins override oncogene-induced senescence by preventing both p53-and RB-dependent pathways and cooperate with these mitogenic oncoproteins to fully transform murine cells, providing them with a tumorigenic potential, when xenografted in nude mice (Ansieau et al., 2008a) . Escape from senescence relies on the ability of TWIST proteins to abrogate p21CIP/WAF1 and p16INK4A transcriptional activation (Ansieau et al., 2008a) . By inhibiting both senescence and apoptotic programs, TWIST proteins are suggested to promote malignant conversion and to provide cells with a growth advantage at the primary site. Accordingly, several studies reported the induction of TWIST1 expression during the progression toward malignant stages in several cancer types including ovary, prostate, bladder, pancreas and hepatic carcinomas, as well as melanomas and pheochromocytomas (Kwok et al., 2005; Li et al., 2006; Ohuchida et al., 2007; Yuen et al., 2007; Zhang et al., 2007; Ansieau et al., 2008a; Waldmann et al., 2009; Yoshida et al., 2009) . Originally described as independent processes, inhibition of failsafe program induction and EMT may turn out to be directly linked. By performing standard cooperation assays in epithelial cells, both TWIST proteins were found to abrogate ERBB2 or RAS V12 -induced senescence and to concomitantly cooperate with these mitogenic oncoproteins in promoting an EMT permitting cellular migration (Ansieau et al., 2008a) . Therefore, reactivation of TWIST genes might simultaneously favor malignant conversion through the inhibition of Rb-and p53-dependent pathways and early cancer cell dissemination through EMT induction. It is noteworthy that the knock-down of the ZEB1, another embryonic transcription factor known to promote EMT, is also associated with senescence program induction , strengthening the link between EMT and senescence escape (Smit and Peeper, 2008; Ansieau et al., 2008b) . Importantly, our laboratory and the Weinberg laboratory recently showed that EMT endows normal and transformed mammary epithelial cells with stemlike properties, including self-renewal capabilities Morel et al., 2008) . Interestingly, both TWIST1 and TWIST2 genes are overexpressed in CD44 þ CD24 -cells, an antigenic phenotype allotted to breast cancer stem cells. Furthermore, ectopic expression of TWIST1 or SNAI1 in immortalized differentiated mammary epithelial cells triggers the gain of the CD44 þ CD24 -phenotype . Collectively, these observations strongly suggest that, in the course of tumor progression, reactivation of EMTinducing transcription factors, including TWIST1 and TWIST2, triggers the generation of cells with selfrenewal capabilities, favoring both the growth of the primary tumor and the initiation of secondary tumors following cell dissemination. Taking into account the role of the microenvironnement in the control of EMT, these observations also suggest that, within a tumor, the acquisition and the maintenance of stem cell properties by tumor cells might be a dynamic and unstable process (Gupta et al., 2009a) .
Additional oncogenic properties have been allotted to TWIST proteins (Figure 2) . By turning-down p53, TWIST embryonic and oncogenic properties S Ansieau et al TWIST proteins also promote chromosomal instability and consequently tumor progression. Accordingly, ectopic expression of TWIST1 in the MCF7 breast cell line induces chromosomal instability and frequencies of chromosomal amplifications are significantly higher in TWIST-expressing breast carcinomas . TWIST proteins additionally provide cells with significant higher resistance to genotoxic and cytotoxic stresses through their ability to induce AKT2 expression or to differently modulate the ratio between the pro-and anti-apoptotic members of the BCL-2 family (see Table 2 ). Associated-EMT might also contribute to TWIST-induced chemoresistance. Growing evidence indeed supports the assumption that EMT is as a transient state providing cells with a higher stress threshold and could thereby constitute an escape from apoptosis. In vitro, oxaliplatin-resistant colorectal cancer cells, tamoxifen-resistant breast cancer cells, gefintinib-resistant lung cancer cells as well as gemcitabineresistant pancreatic cells have been shown to have undergone an EMT (Hiscox et al., 2006; Yang et al., 2006; Rho et al., 2009) . Additional characteristics of 'resistance' in cancer stem cells might also be provided through an EMT, such as lower levels of ROS and consequent protection of their genomes (Diehn et al., 2009) . Therefore, it appears that the acquisition of mesenchymal phenotypes, if even temporarily, engenders tumor cells with a multifaceted capacity to proliferate, migrate, avoid cell death and permanent arrest, as well as protection from extracellular signals and chemistries. At last, TWIST1 promotes tumor formation by favoring neo-angiogenesis, as shown by ectopically expressing the protein in human breast or murine melanoma cell lines Hu et al., 2008) . Interestingly, TWIST1 was also shown to take place downstream of thrombin and to drive thrombin-induced tumor growth, migration and neoangiogenesis (Hu et al., 2008) . Multiple growth factors and receptors including Ang-2, VEGF, KDR, and Groa were defined as positively regulated TWIST target genes (Hu et al., 2008) , highlighting a novel mechanism by which thrombosis contributes to a more malignant phenotype (Nierodzik and Karpatkin, 2006) .
Follow-up questions and perspectives
During cancer progression, reactivation of embryonic EMT-inducing transcription factor-encoding genes, including TWIST1 and TWIST2, is a frequently observed event that should provide cells with critical properties including self-renewal capabilities, resistance to oncogeneinduced failsafe programs and invasive capabilities. Although EMT is a transient process, the acquisition of a propensity to undergo this transdifferentiation process likely favors both the primary tumor growth and cell dissemination. Associated with malignant conversion, reactivation of EMT-inducing transcription factors might foster early cancer cell dissemination (Ansieau et al., 2008a) (Figure 3 ). This assumption is now supported by various results from the Klein laboratory. This group first showed that disseminated tumor cells, isolated from the bone marrow of breast cancer patients, display few chromosomal abnormalities suggesting that they arise from premalignant lesions before the telomeric crisis (Schardt et al., 2005) . In line with this hypothesis, using a transgenic mouse model expressing the ERBB2-activated oncogene in mammary epithelial cells (Di et al., 1999) , they recently confirmed that premalignant cells disseminate from atypical ductal hyperplasia, an early stage in tumorigenesis, in association with Twist1 reactivation (Husemann et al., 2008) . Overall, these data suggest that EMT constitutes a major force driving tumor growth and progression. Although the role of EMT in cancer has long been a matter of discussion, particularly because epithelial cells that have undergone an EMT are phenotypically indistinguishable from native fibroblastic cells, direct evidence of EMT in breast cancer recently arose out of mouse mammary tumor progression model studies (Trimboli et al., 2008) . EMT turns into a mechanism endowing a cell with plasticity and stem-like properties as well as various advantages including chemoresistance, immuno-editing and immune suppression (Moody et al., 2005; Mani et al., 2008; Morel et al., 2008; Kudo-Saito et al., 2009 Figure 2 The oncogenic properties of TWIST proteins stem from their multiple functions. By turning down both RB-and p53-dependent pathways, TWIST proteins override failsafe programs, trigger chromosomal instability and provide cells with chemoresistance. Chemoresistance relies also on the increase of the BCL-2/ Bax ratio and, in epithelial cells, is also associated with the induction of an epithelial-mesenchymal transition (EMT). This transdifferentiation process additionally provides cells with motility and stem-like properties. p53 and RB silencing were found to promote EMT suggesting a potential crosstalk with failsafe program escape. Conversely, EMT might directly contribute to escape from failsafe programs. These assumptions are represented by a dashed line with arrows on each side. By inducing VEGF production, TWIST proteins finally promote the neoangiogenesis.
TWIST embryonic and oncogenic properties S Ansieau et al transcription factors, frequently expressed in cancers, such as ZEB1, ZEB2, the SNAIL zinc-finger protein family, the E47 and TWIST bHLH proteins as well as Goosecoid and FOXC2 (for a recent review see (Polyak and Weinberg, 2009) ). In light of their emerging role in cancer development, targeting EMT-inducers (particularly when their neutralization is associated with restoration of failsafe program functions) may open novel routes for futures therapies. Multiple parameters including the restricted accessibility of nuclear factors, their interplay and functional redundancies, and the large number of pathways downstream in which they partake, unfortunately limit the chance to completely abrogate their activity or to interfere with their activation. However, as exemplified by the increased sensitivity of A549 cells to cisplatin when SNAI1 expression is knocked-down (Zhuo et al., 2008) , combined chemotherapies and EMT inhibition might be fruitful. As a transdifferentiation process, EMT might additionally be associated with the expression (or re-expression) of a set of particular antigens, that could potentially constitute future targets for immune therapies. Interestingly, the Weinberg laboratory recently showed that CD44 þ CD24 -breast cancer cells, that have undergone an EMT, display particular sensitivity to salinomycin, a potassium Figure 3 Reminiscent of their embryonic functions, Twist proteins promote malignant conversion and early cancer cell dissemination through EMT. The mitogenic effect of activated oncoproteins leads to the induction of senescence and apoptosis in premalignant lesions. By downregulating the RB and p53-dependent pathways, TWIST1 and TWIST2, and potentially other functionally related transcription factors promote the progression from benign tumor to malignancy. Importantly, malignant cells co-expressing these embryonic transcription factors and mitogenic oncoproteins are prone to undergo a complete EMT. Consequently, in response to permissive microenvironmental signals, some cells acquire stem-like properties as well as motility and invasive capabilities through this transdifferentiation process. Abbreviations: ND, not defined; NR, not relevant.
TWIST embryonic and oncogenic properties S Ansieau et al ionophore inhibitor, opening a novel route to specifically target these cells (Gupta et al., 2009b) . Hopefully, further knowledge will help in deciphering additional Achille's heels of this process.
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